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Change in core temperature over time can be used as a dependent variable when 
studging the effects of manipulations on neurotransmitter systems. This 
article focuses on the measurement of core temperature as a strategy for 
detecting changes in the status of cholinergic systems. 
Cholinergic neurons participate in the process of thermoregulation and 
interventions affecting them alter the thermal response to cholinomimetics. 
For example, chronic treatment with amitriptyline, chronic swim stress and 
inescapable footshock supersensitize rats to the hypothermic effects of 
oxotremorine. 
This is consistent with the hypothesis that the pathophysiologies of tricyclic 
antidepressant withdrawal phenomena and stress involve supersensitivity of 
muscarinic mechanisms. 
Uses of thermoregulation paradigms for investigating the actions of lithium 
ion, electroconvulsive shock and substances of abuse on muscarinic mechanisms 
are discussed. Applications to problems in the arena of clinical research are 
highlighted. 
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1. Introduction 
This article comments on and reviews the use of temperature as a endpoint in the 
study of cholinergic mechanisms. The cholinergic component of thermoregulation, 
methods of altering it, and the use of core temperature as a dependent measure in 
neuropharmacological studies are discussed. Our objective is to emphasize the power 
of an experimental strategy. The effects of tricyclic antidepressants (TCAS), 
lithium (Li+), antimuscarinic agents, ethanol, opiates, barbiturates, 
cannabinoids, benzodiazepines, electroshock therapy (EST), and chronic stress on 
cholinergic systems are described. 
Dopaminergic (Boschi and Launay, 1985; Colboc and Costentin, 1980; Lin et al, 
1984), noradrenergic (Clark and Clark, 1980a), serotonergic (Ferguson et al, 1985; 
Lin et al, 1981; Simpson and Resch, 1985; Yamauaki, et al, 1983), GABAergic (Serraon 
et al, 1985), peptidergic (Clark and Lipton, 1985), nicotinic (Armitage et al, 1967; 
Dilsaver et al, 1987c; Horstman, 1984; Marks et al, 1983; Marks and Collins, 1984; 
Nordherg and Wahlstrom, 1980) and muscarinic (Clark and Clark, 1980; Lomax et al, 
1969; Lomax, 1970; Lomax and Jenden, 1966; Meyers and Yaksh, 1968) systems partially 
regulate core temperature in mammals. 
Factors complicate the use of thermoregulation paradigms. Organisms vary in their 
thermic responses to drugs. Agents producing a decline in temperature in one 
species cause an increase in another (Lomax et al, 1969). Second, response is 
dependent on the dose and route of administration. Central microinjection of 
acetylcholine (Ach) produces thermogenesis in rats and cats (Beckman and Carlisle, 
1969) but systemic administration of a muscarinic agonist produces hypothermia 
(Dilsaver et al, 1987c; Friedman et al, 1969; Jaffe and Sharpless, 1969). Third, 
experiments are reauired to determine if the response to a centrally active drug is 
due to a central effect. For example, systemically infused cholinergic agonists 
produce hypothermia in rodents. This could be due either to heat loss secondary to 
peripheral vasodilitation or a central action. 
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Experiments described in this article involve the systemic administration of 
agonists. Assuming that a drug penetrates the blood brain barrier, peripheral 
injection leads to delivery to all central sites sensitive to it. A response is the 
summation of all positive and negative effects on a variable. Thus, even if a 
manipulation produces supersensitivity to a muscarinic agonist, one cannot conclude 
all muscarinic sites are supersensitized. Despite this complexity, it is possible 
to devise experiments which allow one to draw inferences about mechanisms underlying 
alterations of the thermoregulatory process. 
2. Principles of Cholinergic Pharmacology 
Certain principles facilitate posing problems amenable to solution using 
thermoregulation paradigms, the use of methods available for manipulating 
cholinergic systems, and the interpretation of data. These are: 
Principle I is "drugs affecting chofinergic systems at least indirectly interact 
with cholinergic receptors." Some agents do so directly, e.g., muscarinic receptors 
(mAchRs) bind muscarinic agonists. However, anticholinesterases indirectly affect 
mAchR mediated changes by inhibiting the hydrolysis of Ach. This principle is not 
absolute. Pharmacological manipulations can change neuronal systems through 
non-specific effects on membrane fluidity. For example, Baron and Kloog (1984) 
reported that the incorporation of certain fatty acids into the cell membrane 
enhanced the sensitivity of mAchRs. However, the assumption that pharmacological 
manipulations alter cholinergic systems through actions on receptors is valid in 
many experimental contexts. One can be reasonably confident of this if the 
properties of the independent variahle used are known. This assumption has 
heuristic value. When dependent and independent variables bear a lawful 
relationship to one another, one might ask, "What could occur at the receptor that 
explains this phenomenon?" This can lead to new experiments to assess whether the 
independent variable is associated with changes in receptor density or affinity, 
alterations in second messenger systems, etc. (Dilsaver, 1986f). 
Principle II: While there are distinct nicotinic receptors (nAchRs) and mAchRs in 
the periphery, it cannot be assumed that the mammalian brain has true nAehRs (Morley 
and Kemp, 1981). However, it does have receptors which bind nicotine (Marks and 
Collins, 1984; Rordberg et al, 1985), a-bungarotoxin (Clarke et al, 1985) and 
neosurugatoxin (Yamada et al, 1985) and which respond to nicotinic agonists. Some 
central cholinoceptors may be sensitive to both musearinic and nicotinic agonists 
(Morley and Kemp, 1981). 
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Some drugs used to study mAchR mediated phenomena have nicotinic effects. 
Pilocarpine is a classic muscarinic agonist, yet it exerts weak nicotinic effects 
(Bowman and Rand, 1980). Physostigmine is used to study contributions of muscarinic 
dysfunction to disturbances of mood (Janowsky et al, 1980), neuroendocrine function 
(Risch et al, 1981. 1983), and polysomnographic parameters (Sitaram and Gillin, 
1980; Sitaram et al, 1979, 1984). However, it diffusely inhibits the hydrolysis of 
Ach. nAchRs, mAchRs and receptors with joint muscarinic-nicotinic sensitivity are 
thus activated. Determining the relative nicotinic and muscarinic effects of this 
drug involves a careful study. Westfall (1973), for instance, reported that Ach 
inhibited the release of norepinephrine in rat brain slices whereas a nicotinic 
agonist promoted its release. The simultaneous administration of a calcium 
chelating agent and Ach resulted in the release of norepinephrine. Ach acts at 
sites sensitive both to muscarinic and nicotinic agonists but the muscarinic 
component of its action is calcium dependent. 
Principle III: Binding data are adynamic measures which convey nothing about the 
function of a system. The literature often equates "supersensitivity" to Ach with 
"up-regulation" or "supersensitive mAchRs." This reflects conceptual error 
(Dilsaver, 1986f). "Up-regulation" is an increase in the maximum density of 
mAchRs. "Supersensitivity" is enhanced behavioral, physiological or biochemical 
responsiveness to agents. It has to do with function. Supersensitivity can be 
receptor independent. Lerer and Belmaker (1982) observed increased sensitivity to 
monoaminergic agonists in the absence of changes in receptor binding parameters. A 
system can be down-regulated and yet be supersensitive if elements comprising it 
become more efficient. For example, intracytosolic mechanisms translating 
agonist-receptor union into functionally relevant events could become more 
responsive to receptor occupation. Consequently, the interrelationship of receptor 
binding data and functional measures provides the most complete account of the 
effects of a manipulation on a neurotransmitter system (Dilsaver, 1986b,f). 
Principle IV: Changes in receptor density or affinity and in the sensitivity of 
an organism to an agonist acting through that receptor can be dissociated in time. 
We measure robust enhancement of the hypothermic response to oxotremorine (0X0) in 
rats after 7-12 days of treatment with amitriptyline (AMI), 10 mg/kg ip twice daily 
(Dilsaver et al, 1987c). Rehavi et al (1980) studied the effects of this regime on 
the binding of tritiated quinuclidinyl bensilate (13~]e~~) in mouse forebrain. 
Seven days of treatment did not produce up-regulation but 21 did. Goldman and 
Erickson (1983) documented a 20% increase in the density of ['H]QNB binding sites 
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in cortex after the treatment of rats with AMI, 10 mg/kg twice daily for 30 days. 
Nomura et al (1982) reported that desipramine (DMI), 10 mg/kg twice daily, increased 
the density of QNB binding sites in rat myocardium and augmented the sensitivity of 
the myocardium to the negative inotropic effects of Ach. Whether central mechanisms 
generally acquire increased sensitivity to muscarinic agonists prior to, 
contemporaneously with or after changes in receptor binding density occurs is not 
kn0Wl. 
Principle V: The value of using a functional parameter as a means of assessing 
the effects of interventions on muscarinic mechanisms is highlighted by considering 
the mAchR subtypes. There are two well-defined mAchR subtypes, designated ml and 
m2' 
These were originally defined by the capacity of the former to specifically 
bind an antagonist, pirenzipine. Pirenzipine binds weakly to mAchR of the heart and 
smooth muscle but potently to receptors in the cerebral cortex, hippocampus, 
sublingual gland and sympathetic ganglia (Birdsall et al, 1984). Ricker and Wescoe 
(1951) first presented evidence that there may be mAchR subtypes when they 
demonstrated that gallamine selectively inhibited effects of methacholine on 
myocardium. The bradycardia produced in anesthetized cats by cholinergic 
stimulation was inhibited by gallamine whereas the hypotension, sweating, salivation 
and enhanced gut motility were not. Rathvun and Hamilton (1970) and Brown and Crout 
(1970) provided similar evidence when they reported that pancuronium exhibited 
cardioselective antimuscarinic effects. They also estimated that the potency of 
gallamine was 100 to 1,000 fold greater in the rat and cat myocardium in vivo than -- 
in guinea pig ileum. An array of specific ml and m2 antagonists and agonists 
are available. However, the pharmacological provocations referred to in this 
article do not implicate a particular receptor subtype. One cannot administer 
specific ml and m2 agonists and antagonists systemically. These drugs lack 
lipid solubility and it is necessary to administer them centrally. Pirenzipine, the 
specific ml antagonist and McN-A-343, a specific m 
1 
agonist are also charged 
molecules. Similarly, Mutschler and Lambrecht (1984) found that the effectiveness 
of specific m2 agonists depends on the quaternization of a ring nitrogen atom--a 
modification limiting the capacity of these analogs to enter the central nervous 
system. 
One can describe a phenomenon hased on the systemic administration of drugs and 
then devise experiments to determine whether it is mediated by an ml or m2 
receptor. Pirenzipine or an ml agonist can be administered centrally should 
peripheral administration suggest that this would be a rewarding experiment. 
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This article focuses on studies involving the systemic administration of 
muscarinic and nicotinic agonists. This approach can be integrated with biochemical 
or molecular strategies. For example, ml agonists activate the 
phosphatidylinositol cycle (Fisher and Dartus, 1985). Supersensitization of a 
muscarinic system associated with interventions discussed below may involve an 
effect on this receptor subtype. The physiological studies can suggest biochemical 
experiments. 
3. Uses of Thermoregulation Strategies in Neurobiological Research 
7.1. Neuropharmacology of Antidepressant Withdrawal Phenomena 
The discontinuation of TCAs produces symptoms suggesting cholinergic overdrive 
(Dilsaver et al, 1987a,h, Dilsaver and &eden, 1984~). First, TCAs produce 
physiological and biochemical evidence of mAchR blockade and bind with specificity 
to central and peripheral mAchRs (Atkinson and Landinsky, 1972; Richelson and 
Dininetz-Romero, 1977; Snyder and Yamamura, 1977). Drugs with these properties 
produce tolerance and hyperexcitability of cholinergic networks (Jaffe and 
Sharpless, 1969). AM1 increased the density of mAchR radioligand sites in mouse and 
rat forebrain (Rehavi et al, 1980; Goldman and Erickson, 1987). Nomura et al, 
(1982) reported that DMI up-regulated mAchR binding sites in rat myocardium. 
Classic antimuscarinic drugs (Ehlert et al, 1983) do this. 
The withdrawal of TCAs can produce three syndromes which are similar to states 
produced by anticholinesterases. These are gastrointestinal distress accompanied by 
anxiety and agitation, movement disorder, and sleep disturbance marked by vivid, 
terrifying dreams and impairment of sleep continuity. These syndromes respond to 
central mAchR blockade (Dilsaver et al, 1983a,b). Withdrawal-precipitated 
cholinergic overdrive has heen posited as their cause (Dilsaver and Greden, 1984c). 
Dilsaver et al (1987c) tested the hypothesis that a TCA can produce cholinergic 
system supersensitivity hy telemetrically measuring temperature in rats (n=15) given 
OX0 before and after treatment with AMI. Telemetric measurements were made using 
the Model VM Mini-Mitter (Mini-Mitter Co, Sun River, OR). This instrument, which is 
surgically implanted into the peritoneal cavity, emits radio waves at a rate 
proportional to temperature. An AM radio serves as a receiver. Time to emit a 
given number of sounds is measured using a digital display stopwatch. This 
measurement is converted to temperature using a linear regression equation derived 
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by measuring the emission rate of the thermosensors at three temperatures in a 
temperature controlled water bath. Tbis instrument can detect a change in 
temperature of O.l"C and remains functional for at least three months. Procedures 
governiag Mini-litter use are available elsewhere (Tocco-Bradley et al, 1985). 
The cbo~inomimet~c induced hypothermia was measured before and after treatment 
with AMI. OX0 Cball8ng8s were preceded by pretreatment with m8thylscopolamine 
nitrate, 1 mg/kg ip, to block peripheral effects of the agonist. Baseline 
temperature was defined as the average of the pre- and post- methylscopolamine 
measurements. These did not differ ia 31 trials (p c 0.1). We measured temperature 
every 15 minutes. Data were analyzed using au ANOYA with repeated measure% and 
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O.lOmg/kgip on days 5,6or7 O.iOmg/kgip repeated 
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Fig 1. Fifteen animals baa Model VM Mini-Mitters implanted. Five days later 
they received challenges, in random order, witb OX0 (base), 0.05, 0.1 or 0.25 m&g 
ip. By day 7 all 15 animals had received all doses of 0X0. Treatment with AMI, 10 
mg/kg ip hid snsued. Those rats retaining functional thermoseosors were again 
subject to challenge with OX0 0.05, 0.10 and 0.25 m&kg ip b8tW88n days 25 and 27. 
An experiment illustrating the effects of treatment with AM1 inVOlV8d challenge 
with 0X0, 0.125 m&kg ip in 11 animal8 given AIUII, 10 m&kg tWiC8 daily for 26 days 
plus 20 mg/kg twice daily for another five days. The maximum decrease (1.51 + 0.19 
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[SEM]) in temperature relative to baseline produced by this dose did not differ from 
that elicited by 0X0, 2.5 m&kg ip in these animals prior to their receiving chrooic 
treatment with AMI (1.17 2 0.11 [SEMI). The hypothermic response produced by 0X0, 
0.1 mg/kg ip after 12-14 days of treatment with AM1 approximated that produced by 1 
m&kg at baseline. Sensitivity to 0X0, 0.05 (p ~0.05) and 0.25 (p <O.OOl) m&kg, 
also increased significantly. Figure 2 illustrates the change in responsiveness of 
the sample (p < 0.001, N=lO) to 0X0, 0.10 mg/kg after chronic treatment with this 
AM1 schedule. The capacity of AH1 to produce supersensitivity to OX0 has been 
confirmed (Dilsaver and Snider, 1987d). Further, multiple injections of OX0 does 
not itself enhance the hypothermic response to subsequent injections (Eciajchrzak nd 
Dilsaver, 1987; Marks and Collins, 1984). 
--- Control 
- AMI 
‘ 1 I I L 8 1 
15 30 45 60 75 90 105 120 
TIME (min) AFTER THE INJECTION OF 
~XOTREMORINE O.lmg/kg ip 
Fig 2. Administration of AI1 augmented the hypothermic response to 0x0. This 
illustrates the difference in responsiveness to OX0 (base), 0.10 mg/kg ip before and 
after 12-16 days of treatment with AMI, 10 mg/kg ip bid in 10 male rata (p <: 0.02, 
ANOVA with repeated measures). 
In summary, data support the hypothesis that at least certain TCA withdrawal 
symptoms are due to cholinergic overdrive. The pathophysiology of affective 
disorders appears to involve eholinergic system supersensitivity (Dilsaver and 
Greden, 1984d, Dilsaver, 1986b-e,g; Janowsky et al, 1980). These experiments 
ironically suggest that AM1 produces an abnormality that may characterize some forms 
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of affective illness (Janowsky et al, 1980, 1983; Risch et al, 1981). The use of 
TCAs and antimuscarinic agents to model the pathophysiology of affective disorders 
was recently discussed (Dilsaver, lg86b,e,g; Dilsaver and Davidson, 1987). 
3.2. The Use of Temperature as a Dependent Variable in Studying Cbolinergic 
Mechanisms in the Neurobiology of Stress 
The interrelationship of stress , cholinergic and aminergic physiology and 
affective disturbance is a developing tbeme (Dilsaver and Alessi, 1986a, 1987a: 
Dilsaver, 1986d-f; Janowsky et al, 1983). Dilsaver et al (1986b) hypothesized that 
chronic stress would produce supersensitivity to 0X0. 0X0-induced hypothermia was 
measured in rats (a=5). Temperature was measured every 15 min for 120 min, before, 
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Fig 3. Design of a study probing tbe effects of chronic swim stress on a 
cbolinergic mechanism involved in the regulation of core temperature. The Model VI 
Mini-Mitter was implanted into the peritoneal cavity of 5 rats on Day 0. On Day 5, 
the animals received OX0 challenge (A). Over the next 5 days the animals were 
subjected to swim stress sessions morning and evening. OX0 challenge B followed the 
last stress session on the morning of Day 10 by 4 hours. OX0 challenges C and D 
followed the final stress sessions by 54 and 196 hours respectively. Please sea 
text for further explanation. 
The study was divided into three phases as depicted in Figure 5. Phase 1: 
Mini-Mitters were implanted into five adult, male rats. The first (I) of five OX0 
challenges marked the end of Phase 1. This challenge provided a baseline against 
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which data from subsequent challenges was evaluated. Phase 2 (stress): This phase 
started with the first of 10 swim stress sessions the evening following the first 
OX0 challenge and ended with the last stress session. The animals were stressed 
morning and evening. OX0 challenges II and III also occurred during Phase 1. 
Challenge II followed the fourth stress session by 2 hours. Challenge III followed 
the tenth and final stress session (which occurred in the morning) by 4 hours. 
Phase 3 (recovery): During this E-day period the animals were not stressed. 
Challenge IV occurred 48 hours after the last stress session. The fifth challenge 
followed 192 hours after the last stress period. 
OX0 Challenge. OX0 challenges were conducted between 1100 and 1400 and were 
preceded by the administration of methylscopolamine nitrate, 1 mg/kg ip. Baseline 
temperature was measured 30 min later. 0X0, 1 mg/kg ip, was then given and 
temperature recorded every 15 min for 120 min. 
Swim Stress. Stress sessions started 5 days after thermosensor implantation. 
Swim stress (Weiss et al, 1981) was employed. Sessions were held morning and 
evening. Duration of the sessions and water temperature were adjusted to produce 
exhaustion since the animals became stronger over the course of the experiment. 
Four hours after the last session, the animals exhibited an enhanced hypothermic 
response relative to baseline (p = 0.0049; ANOVA with repeated measures). The 
supersensitive response was also present 48 hours later (p = O.Ol), and there was a 
highly significant phase effect between challenges I, II and III (p = 0.0003). 
However, 8 days after the last session, responsiveness to OX0 did not differ from 
baseline. Figure 4 illustrates the change in body temperature as a function of time 
during OX0 challenges I-IV. 
Dilsaver and Alessi (1986a, 1987a) gave chronic inescapable footshock to 13 rats. 
Core temperature was measured every 10 minutes for 120 minutes after the injection 
of 0x0. About 24 hours after the fifth stress session, the sample demonstrated 
enhancement of the hypothermic response to OX0 at all 12 time points (p = 0.0002 
sign test). The sample also exhibited an increase in the mean hypothermic response 
to OX0 (p < 0.01, paired t-test). Seven animals received 9 consecutive days of 
inescapable footshock. Twenty-four hours later, 6 exhibited significant enhancement 
of the hypothermic response to oxotremorine at the level of a < 0.05 and the 
sample demonstrated a significant increase in the mean hypothermic response (p< 
0.01, paired t-test). 
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Fig 4. Hypothermic response to OX0 (base) 1 mg/kg ip in a sample (N=5) of rata 
(A) before, and (B) 4, (C) 52, and (D) 192 hours after the last of 10 swim stress 
sessions. A vs B, p = 0.0049, A vs C, p = 0.019: A vs D, n.s. 
In conclusion, chronic forced swim stress and inescapable footshock produced 
cholinergic system supersensitivity. The findings suggest that chronic stress has 
the potential to interact with a central muscarinic mechanisms. The utility the 
thermoregulation paradigms in stress research requires further evaluation. Weiss et 
al (1981) described effects of uncontrollable stressors on biogenic amine 
metabolism, Serotonergic, dopaminergic, and noradrenergic agents can also be used 
to study the effects of stress on aminergic systems (Haggstrom et al, 1984) using 
core temperature as a dependent measure. 
3.3. Use of Temperature as a Dependent Variable to Study the Cholinergic 
Pharmacology of Lithium 
Levy et al (1982) reported that the Li+ prevents the induction of mAchR 
up-regulation by atropine in vivo. Pestronk and Drachman (1980) found that the -- 
Li+ reduced the proliferation of extrajunctional nhchRs in denervated skeletal 
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muscle. These findings raise the possibility that Ii+ down-regulates or 
subsensitizes nicotinic mechanisms. However, Tollefson and Senogles (1982) reported 
that Ii+, 1 mEq/l in vitro, produced a 50% (p -- < 0.05) reduction in the affinity of 
the mAchR and 23% decrease (p < 0.10) in B,,, for [3~]~N~ binding in homogenates 
of human caudate nucleus. They concluded that decreased affinity of ['H]QNB for 
the mAchR in the presence of the Ii+ indicates that the latter is a 
cholinomimetic-like agent. This is based on the assumption that antagonists and 
agonists bind to different sites of the mAchR receptor. Presumably, binding to the 
antagonist site interferes with binding to agonist sites. However, agonists and 
antagonists competitively displace one another. This suggests that they biud to the 
same site (Ehlert et al, 1983). Thus, a 23% reduction in B 
max can also be 
interpreted to suggest that Li+ produces a down-regulation of mAchRs (Dilsaver, 
1984a). 
Lerer and Stanley (1985) presented the strongest data against the hypothesis that 
lithium renders muscarinic networks subaensitive. These investigators reported that 
Li+ enhanced the hypothermic response to pilocarpine in rats and that it 
potentiated the capacity of scopolamine to supersensitize and up-regulate muscarinic 
networks. Hruska et al, (1984) observed that 21 days of treatment with Li 
+ 
reduced the density of [ 3 H]QNB binding sites in homogenates of rat cortex, 
hippocampus and striatum. The mean concentration of Li+ was 0.68 mEq/l in the 
unwashed homogenates. Interestingly, rinsing the homogenates eliminated the 
difference in B,,, between treated and untreated samples. The authors concluded 
that Li+ produces an illusion of mAchR down-regulation. An alternative 
interpretation is that Li+ modifies the physical properties of neurons thereby 
reducing the density of functional available mAchRs (Dilsaver, 1986b). 
Down-regulation is a literal decrease in the density of receptors whereas "decreased 
density of receptors available for binding" implies that receptor density may be 
unchanged but that binding is reduced due to transient modifications such as 
receptor phosphorylation (Burgoyne, 1983) or the alterations of membranes by 
nucleotides or other biochemical factors (Blosser and Appel, 1980; Sokolovsky et al, 
1980). 
Li+ causes an immediate reduction in the density of mAchR binding sites when 
added to an assay medium but its therapeutic effects lag 7 to 10 days. Shou (1980) 
observed that it may not be possible to judge the efficacy of Li+ until a patient 
is treated for up to two years. This suggests that there are effects of chronic 
Li+ that cannot be tapped by a Wcros8 sectional" or in vitro analysis. In vivo -- -- 
studies in animals may better approximate realities of the clinical context. Levy 
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et al (1982) illustrated this. Lithium aborted up-regulation of the mAchR produced 
by atropine but without antecedent pharmacologic perturbation no effect of the ion 
was measurable. 
Will Li.+ preveot AM1 induced supersensitization of the muscarinic mechanism 
involved in producing hypothermia upon cholinomimetic challenge? Tbe data of Levy 
et al (1982) predict that it will, but those of Lerer end Stanley (1985) do not. 
Li+'s eholinergic effects may be important to its therapeutic actions, The 
growing body of information implicating disturbances of muscarinic systems in the 
pathophysiolo~y of affective disorders would be consistent with this. Future 
research in this area could focus on the effects of IX+ on multiple physiological 
functions. 
3.4. Temperature es an Endpoint in Studying the Biology of the Electronconvulsive 
Shock (ECS) 
ECS produces reliable changes in cholinergic physiology. It immediately increases 
the release of Ach and reduces the concentration of this neurotrensmitter in the 
cerebral cortex of animals (Longoni et al, 1976). Chronic ECS continues to produce 
tbese effects (Essman, 1973; Longoni et al, 1976). Man responds similarly to a 
convulsion. Fink (1966) showed that tetrazol-induced seizures produce elevations in 
the cerebral spinal fluid (CSF) concentrations of Ach and choline and tbat ECS 
produces an antimuscarinic reversible increase in slow wave activity. 
Massive release of endogenous agonists (e.g., Ach) or treatment with exogenous 
agonists produces down-regulation of target receptors (Eblert et al, 1980; Dilsever, 
19868; Shifrin end Klein, 1980)). Experts agree that seizures produce mAcbR 
down-regulation. Dashieff et al (1982) observed a 19 to 25% reduction in the 
density of QRB binding sites in rat hippocampus following ECS, one treatment/day for 
four days. Lerer (1984) observed that a single ECS treatment did not affect the 
density of mAchR binding sites in the rat hippocampus or cerebral cortex but that 
one treatment daily for seven days produced decreases of 13 and 15% in the density 
of mAchR radiofigand binding sites in these regions, respectively. 
Reductions in mAcbR density do not necessarily imply a change in function. Eeans 
of relating structural and functional statements amplify the meaning of data in each 
category. Lerer (1984) did this. He measured the effects of ECS on 
thermoregulation end mAchR binding density in rats given ECS once daily for 7 days. 
ECS produced a reduction in the density of mAchR binding sites in the cerebral 
cortex but not the hippocampus. The maximum cataleptic response to pilocarpine wae 
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reduced in animals given ECS (n=lO), once daily for 7 days, relative to sham treated 
animals (p < 0.05). Measurement of the effects of ECS on other cholinergically 
mediated functions, including studies using temperature as a dependent variable are 
now desirable. The strategy of studying the effects of ECS in animals subject to an 
agent producing cholinergic system supersensitivity might be useful. One strategy 
is to determine whether ECS prevents the intensification of the hypothermic response 
to cholinomimetic challenge which follows chronic treatment with mAchR antagonists 
(Dilsaver, 1986b). 
4. Areas for Future Investigation Using Temperature as a Dependent Variable 
Previous sections focused on areas in which study has been conducted. We will now 
deal with areas of theoretical importance. 
4.1. The Pharmacology of Substances of Abuse 
Nonpsychedelic abusable substances frequently activate monoaminergic systems or 
inhibit cholinergic networks by blocking the mAchR or inhibiting the release of Ach 
(Dilsaver, 1987h,i). This section focuses on six categories of abusable agents, 
antimuscarinic agents, barbiturates, benzodiazepines, cannabinoids, ethanol, and 
opiates. These drugs have similar effects on cholinergic mechanisms. 
Antimuscarinic agents block the postsynaptic mAchR and the others inhibit the 
release of Ach from presynaptic nerve terminals. 
Drugs blocking the postsynaptic mAchR may have antidepressant properties (Dilsave, 
1986b,e) and can produce euphoria (Dilsaver, 1987h,i). These agents produce 
up-regulation (Ehlert et al, 1983) and supersensitivity of cholinergic mechanisms 
(Dilsaver et al, 1983b) and their abrupt discontinuation causes symptoms of 
cholinergic rebound (Dilsaver and Greden, 1984c; Dilsaver et al, 1983a,b, 1984b), 
escape of plasma cortisol from suppression by dexamethasone (Dilsaver and Greden, 
19R5) and increased REM density and decreased REM latency (Sitaram et al, 1979). 
The behavioral, neuroendocrine and sleep EEG findings associated with the withdrawal 
of antimuscarinic agents suggest cholinergic overdrive (Dilsaver, 1986e; Dilsaver 
and Davidson, 1987e; Dilsaver and Greden, 1984c; Dilsaver et al, 1983a,b). Agents 
blocking the release of Ach can also produce euphoria. Cannabinoids, opiates, 
barbiturates and ethanol all reduce Ach release from nerve terminals in rodents. 
Depressed mood and affect and somatic symptoms of melancholia often follow the 
discontinuation of these drugs--an observation consistent with some form of the 
cholinergic hypothesis of depression (Dilsaver, 1986b-d,g). 
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Table 1 aummsrisse effecta of antimuscarinic agents, cannabinoids, barbiturates, 
ethanol, and opiates on muscarinic systems. In general, their acute effect is 
antagoui~m of muacarinic cbolinergic systems and potentiatico of the monoamiuergic 
networks whose function is inhibited by eholinergic mechanisms. Cbolinergic- 
monoaminergic interaction is not necessarily antagonistic but tbere is evidence 
that, in addition to the striatum, these syetems exert opposite and counterbalancing 
effects within the mesolimbic system (Friedhoff and Alpert, 1973; Jaeckle and 
Dilsaver, 1986). 
Figure 5 higbligbte the interrelatiooehips of cholinergic and monoaminergic 
systems aa they pertain to the effects of abusable drugs. 
A Cholinergic Monoammergic Interaction Model 
of Affective Regulation 
RAS actwates 
Chohnergtc outflow from 
these structures is Invoked 
I” producmg b~~ioral 
arOUWl 
Electroconical desynchrontration dunng 
behavioral arot& 
R~latioo of transttmns between nonREM 
and REM sleep 
11) and (21 are dependent upon the r&ease of 
acetylchohne at the level of the cerebral cortex 
Fig 5. Cbolinerg~c-Mono~inergic Interaction-Theory of affective regulation. The 
model focuses on mechanisms involved in the regulation of mood and affect, hedonic 
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(RAS) interacts with limhic aminergic nuclei which influence the level of behavioral 
arousal. Cholinergic neurons of the gigantocellular-tegmental field (FTG) interact 
with adrenergic neurons of the locus cereolus to regulate the timing of REM-nonREM 
transitions. The RAS and FTG contain cholinergic neurons with terminals at the 
level of the cerebral cortex. These neurons can affect electrocortical desynchrony 
by releasing Ach. This occurs during behavioral arousal and transitions to REM 
sleep. Cholinergic limbic neurons interact with monoaminergic cells to modulate 
mood, affect, some neuroendocrine functions, psychomotor status and other variables 
relevant to affective and substance abuse disorders. These systems are auto- and 
inter-regulated. Thus, the status of monaminergic variables is related to the- 
status of variables describing the cholinergic limhic nuclei and vice-versa. 
Cholinergic effects of antimuscarinic agents and drugs blocking the release of Ach 
may be related to the pathophysiology of drug dependence and tolerance (Dilsaver, 
1987h). Tolerance to antimuscarinic agents is associated with mAchR up-regulation 
and supersensitivity of cholinergic systems (Dilsaver, 1986b). Other drugs can 
supersensitize cholinergic systems. Marijuana is an example. Cannabinoids produce 
tachycardia, dry mouth, diminished REM sleep, slowing of the electroencorticogram, 
short-term memory deficits and other characteristics of mAchR blockade (Dukes, 1980; 
Jaffe, 1980). They also increase the striatal and amygdalar concentrations of 
Ach--indication of a decrease in the release of Ach (Yoshimura et al, 1974). At 
high concentrations, cannabinoids completely block the release of Ach from 
presynaptic cholinergic neurons at neuromuscular junctions (Kumbarachi and Nastuk, 
1980). Cannabinoids also decrease the release of Ach at muscarinic synapses (Layman 
and Milton, 1971; Revuelta et al, 1979). Assuming sufficient potency, agents with 
this property will induce up-regulation and supersensitivity of cholinergic 
systems. Animal studies and clinical reports are consistent with this. El-Yousef 
et al (1975) observed that chronic marijuana abusers developed severe depression 
upon infusion of physostigmine. Further, delta-'tetrahydrocannabinol potentiates 
the toxicity of this anticholinesterase in rats (Rosenblatt et al, 1972). Dilsaver 
et al (1984b) observed profound depression in an 18-year-old woman who chronically 
abused marijuana and who abruptly discontinued thiothixene and benztropine. 
Withdrawal symptoms included tearfulness, agitation, tenseness of muscles, 
behavioral withdrawal, apathy, quietness or fearfulness, psychomotor slowing, 
sleeplessness for three days, poor self-care, fear of losing her mind, nausea, 
vomiting, anorexia and diarrhea. This syndrome responded to atropine sulfate, 1.2 
mg every 4 hours, without the occurrence of a noteworthy side-effect. We concluded 
that cannabis induced cholinergic system supersensitivity and that psychotropic 
withdrawal triggered a cholinergic overdrive state. 
Ethanol is also a potent inhibitor of the release of Ach (Carmichael and Israel, 
1975). Treatment with ethanol via addition to water produced a 115 to 124% increase 
in the density of QNB binding sites in hippocampal and cortical homogenates 
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(Tabakoff et al, 1979). This change was associated with withdrawal seizures during 
the first 24 hours of abstinence. Smith (1983) administered ethanol, 7% by volume 
in drinking water, to mice for 8 days. The synaptosomal fraction from the brains of 
these animals showed a 128% increase in specific mAchR radioligand binding. Rabin 
et al (1980) also showed that ethanol produces an increased density of QNB binding 
sites in the cerebrum. Soliman and Gabriel (1985) reported that a single injection 
of ethanol resulted in a decrease (p < 0.05) in choline acetyltransferase activity 
in multiple regions of mouse brain but that repeated injection (3 g/kg once daily) 
did not generally result in a further increase in the activity of this enzyme after 
the second or third day. Tolerance also developed to the hypothermic effects of 
ethanol after the third injection. These investigators proposed that tolerance to 
ethanol involves activation of a cholinergic mechanism. Majchazak and Dilsaver 
(1987) recently used the Model VM Mini-Mitter to document that chronic treatment 
with ethanol (14% v:v) produces supersensitivity to the hypothermic effects of 0X0, 
0.25 mg/kg ip, in rats (n=8, p c 0.0001, ANOVA with repeated measures). The results 
of their study is illustrated in Figure 6. The administration of 0X0, 0.25 mg/kg ip 
every other day for 10 days failed to alter the thermic response to this muscarinic 
agonist. This strongly suggests that ethanol supersensitizes a muscarinic 
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Fig 6. Eight adult male Sprague-Dawley rats were challenged with 0X0, 0.25 mg/kg 
before and after treatment with 14% ethanol (v:v) in drinking water. The change in 
hypothermic response was significant at the 0.0001 level (ANOVA with repeated 
measures). Ninety-six (96) hours after the discontinuation the animals remained 
supersensitive (p c 0.02). 
20 S. C. Dilsaver and N. E. Alessi 
Pentobarbitol inhibits the release of Ach (Domino and Wilson, 1972, 1973; 
Schuberth et al, 1969) and the withdrawal of a barbiturate increases the utilization 
and turnover of Ach (WahlstrBm and Norberg, 1979). The latter finding indicates 
enhanced release of Ach during the withdrawal phase. Wahlstrijm (1978) reported that 
chronic treatment with barbital produced supersensitivity to choline as inferred 
from the threshold to induction of seizures. Wahlstrsm and Ekwall (1976) showed 
that animals chronically treated with barbital demonstrate supersensitivity to the 
hypothermic effects of pilocarpine. Finally, the chronic administration of 
barbiturates produced up-regulation of mAchRs in the brains of rats (Nordberg and 
Wahlstrb;m, 1979, 1980). Thus, acute treatment with a barbiturate decreases the 
release of Ach and chronic administration produces up-regulation and 
supersensitivity of muscarinic mechanisms. 
Opiate agonists also inhibit the release of Ach and could supersensitize 
muscarinic systems (Jhamandas et al, 1970; Paton, 1957). The withdrawal of opiates 
produces signs and symptoms of cholinergic overdrive states (Dilsaver, 1987h). 
Tbese include nausea, vomiting, anorexia, diarrhea, myalgeas, insomnia, anxiety, 
coryza, irritability, cephalgia, dizzyness, tachycardia and hypertension. The 
withdrawal of TCAs or the intravenous injection of physostigmine or arecoline also 
produce these (Dilsaver, 1983b; Dilsaver and Greden, 1984c). While opiate 
withdrawal states are too complex to be explained by a cholinergic mechanism alone, 
it is conceivable that they involve a cholinergic component. 
The effects of benzodiazepines on the mAchR mediated fall in core temperature is 
of theoretical interest. Benzodiazepines facilitate the binding of yaminobutyric 
acid (GABA) to its receptor. There are reports that GABA inhibits the release of 
Ach (Agardh et al, 1985; Giotti et al, 1985; Schultz and Lund, 1983; Wood and 
Richard, 1982). Injection of the GABA agonist, muscimol, into the septum decreases 
the turnover of Ach in the hippocampus (Wood et al, 1979). This implies a decreased 
release of Ach. The regulation of Ach release by GABA in this region is consistent 
with tne neuroanatomical finding that there is a large population of GABAergic 
interneurons in the septum (Fonnum and Walaas, 1978). Chronic treatment with 
benzodiazepines might inhibit the release of Ach from presynaptic terminals and 
thereby denervate cholinergic neurons. The result should be enhancement of the 
hypothermic response to muscarinic agonists. 
Table 1 lists the sites at which the six groups of abusable agents discussed above 
act upon muscarinic systems, the effects of their actions at these loci, and the 
known or predicted impact of chronic treatment with these drugs upon the 
cholinomimetic induced fall in core temperature. Note that all six classes can 
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produce euphoria or have anxiolytic properties. Cholinergic mechanisms were long 
ago accorded a role in the pathophysiology of mood disorders (Dilsaver, 1986b-e) and 
more recently were proposed to be involved in the neurobiology of stress (Dilsaver 
and Alessi, 1987a; Janowsky et al, 1983) and anxiety (Dilsaver, 1986f). Direct 
blockade of postsynaptic mAchRs or inhibition of the release of Ach might be linked 
to the euphoriagenic and anxiolytic properties of these agents. However, their 
effect is to up-regulate and supersensitize muscarinic systems. This raises 
important questions. First, "Do these compensatory changes in cholinergic networks 
limit the long-term clinical utility of certain anxiolytics?: Secondly, "Does 
tolerance and addiction to the therapeutic effects of benzodiazepines involve 
up-regulation and supersensitivity of cholinergic systems?" One might speculate 
that anxiolytics and antidepressants devoid of a capacity to up-regulate and 
supersensitize cholinergic systems would, ceteris paribus, be less apt to produce 
tolerance and physiological addiction. 
In conclusion, several substances of abuse inhibit cholinergic systems by blocking 
the postsynaptic mAchR or decreasing the release of Ach. These result in the 
supersensitization of cholinergic systems. The significance of these factors to the 
biology of dependence, tolerance and withdrawal phenomena is unknown. Physiological 
endpoints sensitive to cholinergic agonists, such as temperature, may be useful in 
studying the actions of some of these agents on cholinergic systems. 
4.2. Applications to Clinical Research 
Body temperature can be measured telemetrically in man. Dabbs and Neuman (1978) 
used a pulse-modulated radio frequency transmitter mounted to the ear to measure 
temperature against the ear drum. The device has the appearance of a hearing aid. 
The system was comprised of a temperature sensor and transmitter, a device for 
mounting these, a receiver and an instrument for decoding the signal recorded. The 
transmitter consisted of a temperature sensor, multivibrator and radio frequency 
oscillator. The resistance of the sensor is regulated by temperature and determines 
the oscillatory frequency of a multivibrator. Pulse frequency is proportional to 
temperature. A thermistor can also be used to manually measure rectal temperature 
at specified intervals (Avery et al, 1982) or a rectal probe attached to a computer 
system can automatically record temperature (Henane et al, 1973). 
REM latency, duration of the first REM period, elevated REM density, and core 
temperature retain their typical relationship during depressive episodes (Avery et 
al, 1982; Czeisler et al, 1980; Schultz and Lund, 1983). Treatment with scopolamine 
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followed by an abrupt withdrawal produced changes in REM sleep simulating those 
marking primary depression (Sitaram et al, 1979). These findings suggest an 
interesting question. "Does treatment with an antimuscarinic agent produce 
simultaneous phase advance of the REM and sleep-temperature cycles in normal man?" 
If so, a particular neurotranamitter mechanism ia implicated in the pathophysiology 
of both REM sleep and the altered temperature activity cycle in the affective 
disorders. 
Thermoregulation strategies can also be used to study the effects of agents on 
cholinoceptive neurons. For example, evidence that chronic treatment with TCAs 
supersensitizes muscarinic mechanisms could be strengthened by demonstrating that 
the withdrawal of these agents produces a atropine sensitive decrease in a body 
temperature over time. This might occur if withdrawal of a TCA produces cbolinergic 
overdrive at the critical thermoregulatory sites. Challenge with a cholinergic 
agonist before and after chronic treatment with a TCA would be a more powerful means 
of demonstrating supersensitization of the pertinent neurons. Establishing that 
TCAs supersensitize cbolinoreceptive neurons using this strategy would be consistent 
with reports that the withdrawal of TCAs produces an increased frequency in positive 
dexamethasone suppression teat (DST) results (p = 0.03) and an increase in the 
absolute concentration of plasma cortiaol (p < 0.0033) post-dexamethasone challenge 
(Dilsaver and Greden, 1984e, 1985) and REM rebound (Dunleavy et al, 1972). 
Effects of Li+ on cholinergic physiology can also be studied using a 
thermoregulation paradigm. One strategy would be to measure the thermal response to 
a cholinergic agent before withdrawal of Li+ in euthymic patients and again a few 
weeks after the last dose, provided patients remain in remission. Both consistently 
increased or decreased sensitivity to the muscarinic agonist during lithium 
prophylaxis would be of interest. 
Responsiveness of core temperature to cholinergic drugs might provide a simple 
means of testing the hypothesis that subjects with certain types of depressive 
disorders have supersensitive cholinergic systems. Rapidly-cycling patients are 
ideal for this study. According to existing theory, drug-free patients who 
rapidly-cycle should exhibit greater changes in body temperature in response to 
cbolinergic challenge during the depressed phase than euthymic or manic phases 
(Dilsaver and Greden, 1984d). 
The questions proposed here for clinical study using a thermoregulation paradigm 
all allow patients to be their own controls. Using subjects as their own controls 
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tends to minimize variance at a fixed sample size and the number of subjects 
required to obtain meaningful results. 
Use of cholinergic agents in human subjects is warranted and feasible. Human Use 
Committees have approved the use of arecoline (Sitaram et al, 1979) and 
physoatigmine (Janowsky et al, 1980, 1983; Risch et al, 1981, 1983). Thus, the 
thermoregulation studies proposed are possible. 
5. Conclusions 
Measurement of core temperature provides a means of quantifying effects of 
pharmacological manipulations on cbolinergic systems. The process of 
tbermoregulation involves central and peripheral mechanisms but studies can be 
designed which justify the conclusion that central mechanisms generate a given 
result. Many behavioral, physiological and biochemical measures are useful as 
dependent variables when studying central functions in health or disease. 
Abnormalities of these variables can result from changes in the density of a 
particular type of receptor or alteration of the sensitivity of neurons to a 
transmitter (Dilsaver, 1986b). Pathology can be modeled by pharmacologically 
inducing changes in the physiology of neurotransmitter networks (Dilsaver, 
1986b,e,f). Mood and affect (Dilsaver, 1986b), psychomotor function (Creden and 
Carroll, 1981), hedonic capacity (Dilsaver, 1986b), pupillary physiology (Soli et 
al, 1980), sleep architecture (Sitaram and Gillin, 1980), neuroendocrine variables 
(c arroll, 1982; Dilsaver, 1986b,e,f), power spectral analysis (Duffy et al, 1979), 
rates of cyclic GMP generation (Kanba and Ricbelson, 1984), or pbospbolipid turnover 
(Berridge and Irvine, 1984; Fisher and Agranoff, 1985; Fisher and Bartus, 1985), and 
core temperature are all useful dependent variables in psychopharmacological study 
(Dilaver, 1986b). However, none is measured with greater ease and economy of 
expense than core temperature. Perhaps it is underutilized: 
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